Jaypirca Gains Approval as First Non-Covalent BTK Inhibitor for CLL/SLL
INDIANAPOLIS, September 8, 2025 — Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, has demonstrated a...
Immunotherapy
Advertisement
Oncolytics Biotech Shows Favorable Safety for Pelareorep in GI Tumors
SAN DIEGO, Sept. 2, 2025 – Oncolytics Biotech® Inc. (Nasdaq: ONCY), a clinical-stage immunotherapy company, announced updated clinical safety...
FDA Approves Precigen’s PAPZIMEOS, First Immunotherapy for Recurrent Respiratory Papillomatosis
August 19, 2025 — Germantown, MD – Precigen, Inc. (NASDAQ: PGEN) today announced that the U.S. Food and Drug...
Advertisement
